lusutrombopag lusutrombopag lusutrombopag, sold under the brand name mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. it is being manufactured and marketed in japan by shionogi. it was approved by the u.s. food and drug administration (fda) in july 2018, and nice in january 2020. lusutrombopagclinical datapronunciationloo" soo trom' boe pag trade namesmulpleta, mulpleoahfs/drugs.commonographmedlineplusa618043license data eu ema: by inn us dailymed: lusutrombopag routes ofadministrationby mouthatc codeb02bx07 (who) legal statuslegal status us: ℞-only eu: rx-only in general: ℞ (prescription only) identifiers iupac name (e)-3--2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid cas number1110766-97-6 ypubchem cid49843517drugbankdb13125 ychemspider21106301 yunii6ll5jfu42fkeggd10476chemblchembl461101 nchemical and physical dataformulac29h32cl2n2o5smolar mass591.54 g·mol−13d model (jsmol)interactive image smiles cccccco(c)c1cccc(-c2csc(nc(=o)c3cc(cl)c(/c=c(\c)c(=o)o)c(cl)c3)n2)c1oc inchi inchi=1s/c29h32cl2n2o5s/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18h,5-8,12h2,1-4h3,(h,35,36)(h,32,33,34)/b17-13+/t18-/m0/s1 ykey:nozijmhmkorzba-kjcuyjgmsa-n y ny (what is this?) it was approved for medical use in the european union in february 2019.